AZD6750 / AstraZeneca - LARVOL DELTA

AZD6750: Design and Efficacy of a CD8-guided IL-2 That Enhances CD8 T Cell Function (SITC 2025) - "This approach potentially limits the side effects of Aldesleukin, typically attributed to the broad effects of IL-2R signalling, which should result in a safer, more effective IL-2 that has the potential to provide benefit to larger numbers of patients.Methods In vitro, proliferation of human PBMCs and antigen-specific tumor cytolysis were evaluated after treatment with AZD6750, Aldesleukin or an unguided-IL-2 mutein. Studies were performed in accordance with the UK Animal (Scientific Procedures) Act 1986 and the EU Directive 86/609, under a UK Home Office Project License, using guidelines outlined by Workman and colleagues and the UKCCR guidance. All patient samples were obtained with written informed consent and studies were conducted in accordance with recognized ethical guidelines (Declaration of Helsinki) and were approved by the East of England - Cambridge East Research Ethics Committee (HTA license number 12109)."

Clinical • Oncology • CD8 • FCGR2A • FCGR2B • IFNG • IL2 • IL2RA • IL2RG

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Apr 2029 ➔ Oct 2029 | Trial primary completion date: Apr 2029 ➔ Oct 2029

Trial completion date • Trial primary completion date • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Genito-urinary Cancer • Head and Neck Cancer • High Grade Serous Ovarian Cancer • Lung Cancer • Melanoma • Merkel Cell Carcinoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Genito-urinary Cancer • Head and Neck Cancer • High Grade Serous Ovarian Cancer • Lung Cancer • Melanoma • Merkel Cell Carcinoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=60 | Not yet recruiting | Sponsor: AstraZeneca

New P1/2 trial • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Genito-urinary Cancer • Head and Neck Cancer • High Grade Serous Ovarian Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Melanoma • Merkel Cell Carcinoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer